Abstract: This disclosure describes the first viable non-enzyme protein encapsulated within an aerogel. In this, a large excess of cyt c is added to a commercial buffered Au sol solution ( ) which results in the formation of a gold˜protein-protein superstructure in the absence of separation techniques which destroy the superstructure. The gold˜protein-protein superstructure is then nanoglued into a silica framework during the sol to gel transition. To form the gel, the Au˜cyt. c superstructure in buffered medium is added to a silica sol and the composite gels are washed with acetone followed by liquid carbon dioxide and then supercritically dried to form the aerogel. The biocomposite aerogels have a multiplicity of applications particularly in the realm of sensing and energy transformation.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Abstract: The invention relates to methods of determining islet cell activity by detecting the level of Archipelin or a fragment thereof and comparing the level to a baseline level or range associated with a known islet cell activity. Such methods are useful in diagnosing and studying the development of diabetes.

Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.

Abstract: The present invention relates to a new member of the serine protease family, Ztryp3. Members of this family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. These enzymes are also used in a variety of diagnostic, therapeutic, and industrial contexts.

Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme, antibodies to such enzyme, and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.

Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.

Abstract: This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.

Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.

Abstract: A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose.

Abstract: A method for treating or preventing infarction of a patient comprising administering a hepsin antagonist with a dosage effective to suppress or inactivate hepsin's expression over a sustained period.

Abstract: The present invention relates to a method of designing an ion channel blocker for an ion channel which includes providing an ion channel having an external vestibule portion and raising an antibody, binding portion, probe, or ligand specific to the external vestibule portion of the ion channel, where the antibody, binding portion, probe, or ligand inhibits ion transport through the ion channel. The present invention further relates to a method of inhibiting ion transport through an ion channel, a method for screening a drug for effectiveness as an ion channel blocker, and an antibody, binding portion, probe, or ligand.

Abstract: This invention provides for antibodies directed to OLD-35 protein, the product of the OLD-35 gene, which displays enhanced expression during cellular senescence and terminal cell differentiation.

Abstract: A method of treating a condition associated with heparanase expression by administering a heparanase activity neutralizing monoclonal anti-heparanase antibody, the monoclonal anti-heparanase antibody being for neutralizing heparanase catalytic activity.

Abstract: The present invention relates to sperm specific surface proteins, nucleic acid sequences encoding those proteins and antibodies raised against those proteins. Compositions comprising the sperm specific proteins or inhibitors of said proteins can be used in contraceptive applications.

Abstract: The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins allowing their systemic absorption through the gastric and mucosal district. Immunoglobulins have a different specificity depending on the required therapeutic effect. They are used in passive immunoprophylaxis for the prevention or therapy of infections caused by pathogenic agents such as virus, bacteria, parasites, or they are used in the modulation of endogenous bio-chemical balances, or in the detoxification from drugs of abuse, medicines, toxins.

Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

Abstract: The invention provides methods and compositions for alleviating the symptoms of neuropathic conditions with a pharmaceutical composition including an effective amount of anti-glutamic acid decarboxylase (anti-GAD) antibodies.

Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.

Abstract: A novel gene (designated 30P3C8) and its encoded protein is described. 30P3C8 exhibits restricted tissue expression in normal adult tissue and is overexpressed in prostate tissue xenografts, providing evidence that it is aberrantly expressed in at least some prostate cancers. Consequently, 30P3C8 provides a diagnostic and/or therapeutic target for prostate cancers.

Abstract: The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.

Abstract: This invention relates to methods and compositions to regulate biofilm formation. In particular, the invention relates to regulation of biofilm formation by modulating the GacA/GacS regulatory system.

Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin &agr;v&bgr;3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing &agr;v&bgr;3 antagonists.

Abstract: MAT II &bgr; subunit proteins and cDNAs encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MAT II &bgr; subunit homologs, and methods of producing the same, are also disclosed. MAT II &bgr; subunit gene products are characterized as having activity in modulating the biological activity of MAT II. Thus, therapeutic methods involving these activities are also disclosed.

Abstract: A novel phospholipase A1 (PLA1) having a substrate specificity for phosphatidic acid (PA): a peptide or a polypeptide originating in the novel PLA1: a polynucleotide encoding the peptide or the polypeptide originating in the novel PLA1: a process for producing the peptide or the polypeptide originating in the novel PLA1: an antibody against the peptide or the polypeptide originating in the novel PLA1: a method of identifying an inhibitor, an antagonist or a potentiator for the novel PLA1 by using the same: a compound identified by this method: and medicinal compositions and a diagnostic method with the use of the same.

Abstract: Provided are methods of using a modulator of Notch IC protease activity in the manufacture of a medicament for use in immunotherapy and methods of detecting such a modulator.

Abstract: The present invention discloses polynucleotides which identify and encode pD52 or pRA006 as well as novel functions for the D52 gene family (pD52) which are specifically expressed in the embryonic pancreatic epithelium, in islet cells of the pancreas, in adipocytes, and in intestinal crypt cells. The invention also discloses novel function for the RA006 gene family (pRA006) which are specifically expressed in a subset of islet cells of the pancreas, the eye, as well as the central and peripheral nervous system. The invention provides for compositions for disorders associated with the expression of pD52 or pRA006, such as for the treatment, alleviation and/or prevention of metabolic disorder or metabolic syndrome, such as pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), obesity, adipositas, eating disorders (bulimia nervosa, anorexia nervosa), cachexia (wasting), and neurodegenerative disorders, and other diseases and disorders.

Abstract: A method of identifying a hair growth modulator (i.e., hair growth inhibitor or inducer) which comprises identifying a P-cadherin modulator (i.e., P-cadherin inhibitor or inducer); and testing whether the P-cadherin modulator is functional as a hair growth modulator.

Abstract: A subject of the invention is the use of lysyl oxidase inhibitors in the context of the implementation of in vitro cell culture methods which are capable of being used in tissue therapy, or cell therapy, or in experimental pharmacology.

Abstract: Compositions and methods involving agents that specifically bind to methylthioadenosine phosphorylase (MTAP) protein are disclosed. Illustrative compositions comprise binding agents that bind to human MTAP protein in biological samples, including embedded samples. The binding agents are useful, for example, in the detection, prognosis, and/or treatment of MTAP deficient cancers. Also disclosed are kits containing the reagents necessary for the detection of human MTAP protein in an embedded sample.

Abstract: The present invention relates to methods of inhibiting heparanase activity and treating various conditions by administering to an animal an effective amount of an immunogen that elicits an immune response to heparanase. According to the present invention, the immunogen is heparanase or a fragment thereof and, preferably, the immunogen is an antigen presenting cell (APC), such as a dendritic cell (DC), displaying heparanase or a fragment thereof on the surface. The present invention also relates to compositions containing the immunogen.

Abstract: The present invention relates to methods and compositions for the amelioration of symptoms mediated by the collagenolytic activity of cathepsin K complex. The invention provides methods of specifically modulating the collagenolytic activity of cathepsin K without substantial interference in other biologically-relevant activities of cathepsin K.

Abstract: The invention relates to the use of an IKK-&bgr; inhibitor for the production of a medicament for the treatment or prevention of atheroscieroses. A screening method for the discovery of IKK-&bgr; inhibitors in endothelial cells is also disclosed. The method involves the contacting of a potential inhibitor with activated endothelial cells and a determination of the secretion of MCP-1 from the endothelial cells.

Abstract: This disclosure describes the first viable non-enzyme protein encapsulated within an aerogel. In this, a large excess of cyt. c is added to a commercial buffered Au sot solution ( ) which results in the formation of a gold˜protein-protein superstructure in the absence of separation techniques which destroy the superstructure. The gold˜protein-protein superstructure is then nanoglued into a silica framework during the sol to gel transition. To form the gel, the Au-cyt. c superstructure in buffered medium is added to a silica sol and the composite gels are washed with acetone followed by liquid carbon dioxide and then supercritically dried to form the aerogel. The biocomposite aerogels have a multiplicity of applications particularly in the realm of sensing and energy transformation.

Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.

Abstract: Substantially pure human cyclin-dependent kinase-like proteins PITALRE and PISSLRE and isolated protein complexes that comprise PITALRE or PISSLRE are disclosed. Isolated nucleic acid molecule that encode PITALRE or PISSLRE, or a fragment thereof; recombinant expression vectors that comprise nucleic acid sequence that encode PITALRE or PISSLRE; and host cells that comprise such recombinant expression vectors are disclosed. Oligonucleotide molecules that consist of a nucleotide sequence complimentary to a portion of the nucleotide sequence that encodes PITALRE or PISSLRE are disclosed. Antibodies which bind to epitopes on PITALRE or PISSLRE are disclosed. Nucleic acid molecules that comprise a nucleotide sequence that encodes phosphorylation deficient PITALRE, or a phosphorylation deficient PI SSLRE; recombinant vectors and pharmaceutical compositions that comprise such nucleotide sequences are also disclosed. Methods of identifying compounds which inhibit PITALRE activity are disclosed.

Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide or an antibody thereto.

Abstract: Novel methods of inhibiting angiogenesis or tumorigenesis with compositions that inhibit the apelin/APJ signaling pathway are provided. Also provided are methods of promoting angiogenesis or tumorigenesis with compositions comprising an apelin polypeptide or small molecule agonist. The present invention further provides methods for identifying therapeutic agents that affect angiogenesis.

Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.

Abstract: Chimeric, humanized and other RANK-L mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: Means and method for at least partial inhibition of tumor growth are provided. Methods makes use of binding molecules capable of specifically binding to an epitope present on a subset of fibronectin proteins. By providing an individual with a binding molecule of the invention it is possible to interfere with sites of angiogenesis or sites that seen active angiogenesis in the recent past. Through this interference blood flow is at least in part inhibited. Through this inhibition it is possible to at least in part inhibit processes dependent on active angiogenesis in said individual, such as tumor growth.

Abstract: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.

Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and are important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic, prognostic or staging methods and compositions using such antibodies or fragments thereof are also provided. The methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.

Abstract: Antibodies directed against laiminin B1k are provided.